Share on StockTwits

Thoratec (NASDAQ:THOR) has received an average recommendation of “Buy” from the fifteen ratings firms that are currently covering the stock, AR Network reports. Four research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $42.67.

THOR has been the subject of a number of recent research reports. Analysts at TheStreet downgraded shares of Thoratec from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Thoratec in a research note on Wednesday, May 21st. They now have a $33.00 price target on the stock. Finally, analysts at Citigroup Inc. reiterated an “overweight” rating on shares of Thoratec in a research note on Wednesday, May 7th. They now have a $43.00 price target on the stock, down previously from $45.00.

Shares of Thoratec (NASDAQ:THOR) traded down 0.34% on Tuesday, hitting $33.945. 24,643 shares of the company’s stock traded hands. Thoratec has a 52 week low of $30.01 and a 52 week high of $43.58. The stock has a 50-day moving average of $32.6 and a 200-day moving average of $35.25. The company has a market cap of $1.928 billion and a P/E ratio of 26.82.

Thoratec (NASDAQ:THOR) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.02. The company had revenue of $125.70 million for the quarter, compared to the consensus estimate of $122.56 million. During the same quarter in the previous year, the company posted $0.41 earnings per share. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. Analysts expect that Thoratec will post $1.77 EPS for the current fiscal year.

In other Thoratec news, Director Neil F. Dimick sold 4,158 shares of the stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $32.15, for a total value of $133,679.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Thoratec Corporation is engaged in mechanical circulatory support with a product portfolio to treat the range of clinical needs for advanced heart failure (NASDAQ:THOR) patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.